Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02986087

Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia

Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Cincinnati Children's Hospital Medical Center (CCHMC)

Cincinnati, Ohio, 45229, United States

Location status: Recruiting

Location contact

Foong Y Lim, MD

PRINCIPAL_INVESTIGATOR

Foong-Yen Lim, MD

CONTACT

[email protected]

513-803-5270

Jose L Peiro, MD, MBA

SUB_INVESTIGATOR

Jose L Peiro, MD, PhD, MBA

CONTACT

[email protected]

513-803-4563

About this study

Fetuses with congenital diaphragmatic hernia with liver-up, and an observed to expected lung-to-head ratio of <25%, LHR <1, or a moderate category with o/e LHR <30%, singleton pregnancy, no known other anomalies, gestational age < 29 weeks 6 days (severe), gestational age < 31 weeks 6 days (moderate), no maternal disease, maternal age > 18 years old…. meet criteria to be offered fetal tracheal occlusion. We want to test feasibility and efficacy in our center.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Isolated CDH with liver up
  • Severe pulmonary hypoplasia with ultrasound O/E LHR <25% at the time of surgery
  • Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days
  • Moderate pulmonary hypoplasia with ultrasound O/E LHR <30% and liver-up at the time of surgery
  • Gestational age at FETO procedure 30 weeks 0 days to 31 weeks 6 days in this moderate category
  • Maternal age greater than or equal to 18 years
  • Gestational age at enrollment prior to 29 weeks 6 days, or 31 weeks 6 days in moderate category
  • Normal karyotype or FISH
  • Normal fetal echocardiogram
  • Singleton pregnancy
  • Willing to remain in the greater Cincinnati area for remainder of pregnancy
  • Family considered and decline option of termination of the pregnancy at less than 24 weeks 0 days
  • Family meets psychosocial criteria

Exclusion criteria

  • Patient < 18 years old
  • Multi-fetal pregnancy
  • Rubber latex allergy
  • Preterm labor, cervix shortened (<15 mm) or uterine anomaly strongly predisposing to preterm labor, placenta previa
  • Bilateral CDH, isolated left sided CDH with an O/E > 30%
  • Additional fetal anomaly by ultrasound, MRI, or echocardiogram
  • Chromosomal abnormalities
  • Maternal contraindications to fetoscopic surgery or severe maternal condition in pregnancy
  • Incompetent cervix with or without a cerclage
  • Placental abnormalities known at time of enrollment
  • Maternal HIV, Hepatits B, Hepatitis C
  • Maternal uterine anomaly
  • No safe or technically feasible fetoscopic approach to balloon placement
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy

Treatment and study plan

Fetal Tracheal Occlusion

Device

Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of <25%, LHR <1, o/e LHR<30% (moderate), singleton pregnancy, no known other anomalies, gestational age < 29 weeks 6 days, no maternal disease, maternal age > 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center.

Other names: FETO, Fetal Endoluminal Tracheal Occlusion

Primary outcomes

  1. Change lung growth on prenatal imaging

    Time frame: prenatal period up to 40 weeks gestation

    Change in o/eLHR and other prenatal imaging tests

Secondary outcomes

  1. Change survival in the severe congenital diaphragmatic hernia subgroup

    Time frame: 6 months

    Change rate of survival

  2. Change need for ECMO therapy

    Time frame: 6 months

    Change need for ECMO therapy

  3. Change pulmonary hypertension

    Time frame: 6 months

    Change pulmonary hypertension

  4. Change neonatal morbidity

    Time frame: 1 year

    Change neonatal morbidity

Study contacts

Contact information is provided by the study sponsor or research team.

Foong-Yen Lim, MD

CONTACT

[email protected]

(513) 636-6259

Jose Peiro, MD, PhD

CONTACT

[email protected]

(513) 803-4563

Sponsors and collaborators

Lead sponsor

Children's Hospital Medical Center, Cincinnati

Other

Registry information

Acronym: FETO

Important dates

Study start
2016
Primary completion
2025
Study completion
2026
First posted
Dec 8, 2016
Registry last updated
May 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.